With an eye to development and internationalization, Molteni Farmaceutici constantly pursues chemical-pharmaceutical, clinical and biomedical research to develop new drugs and improve therapeutic applications.
The company’s primary goal is to devise treatments able to improve the patient’s quality of life, by mitigating the side effects of narcotic analgesics while simultaneously increasing patient compliance.
Pain treatment, addiction and anesthetics are the therapeutic areas with a high health and social impact in which Molteni Farmaceutici is a European leader.
Living without pain is a right everyone is entitled to. Italian Law no. 38, issued in 2010, safeguards and guarantees for the first time access to pain treatment and palliative care, respecting the dignity and autonomy of the human person.
To help clinicians institute proper treatment schedules against unnecessary suffering, Molteni Farmaceutici has always been involved in developing, manufacturing and marketing products for the treatment of pain, from morphine derivatives, whose production Molteni started in the early 19th century, up to the most recent opioids: a nasal spray developed in the USA for severe breakthrough cancer pain, for which Molteni has been granted the exclusive manufacturing rights for Europe.